Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Income (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Non Operating Income data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Non Operating Income fell 14.91% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $10.3 million, down 28.28%, while the annual FY2025 figure was $10.3 million, 28.28% down from the prior year.
  • Non Operating Income reached $2.8 million in Q4 2025 per CCCC's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.9 million in Q1 2024 and bottomed at -$464000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $1.6 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: tumbled 354.9% in 2021, then skyrocketed 5978.57% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$403000.0 in 2021, then skyrocketed by 374.94% to $1.1 million in 2022, then surged by 166.25% to $2.9 million in 2023, then increased by 10.75% to $3.3 million in 2024, then dropped by 14.91% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $2.8 million in Q4 2025, $2.2 million in Q3 2025, and $2.5 million in Q2 2025.